002880 卫光生物
已收盘 07-10 15:00:00
资讯
新帖
简况
卫光生物：卫光生命科学园再获殊荣，行业标杆意义凸显
市场资讯 · 07-09 09:40
卫光生物：卫光生命科学园再获殊荣，行业标杆意义凸显
卫光生物：原料血浆供应总体能满足生产需要
证券之星 · 07-02
卫光生物：原料血浆供应总体能满足生产需要
卫光生物收盘下跌1.46%，滚动市盈率26.26倍，总市值65.77亿元
金融界 · 07-02
卫光生物收盘下跌1.46%，滚动市盈率26.26倍，总市值65.77亿元
卫光生物：7月17日将召开2025年第一次临时股东大会
证券日报网 · 07-01
卫光生物：7月17日将召开2025年第一次临时股东大会
卫光生物：坚持内生式增长和外延式并购双驱并进
证券之星 · 06-25
卫光生物：坚持内生式增长和外延式并购双驱并进
卫光生物：公司研发实力不断提升
证券之星 · 06-24
卫光生物：公司研发实力不断提升
卫光生物最新公告：获得医疗器械生产备案凭证
证券之星 · 06-16
卫光生物最新公告：获得医疗器械生产备案凭证
血液制品概念盘中跳水，卫光生物跌0.21%
市场透视 · 06-11
血液制品概念盘中跳水，卫光生物跌0.21%
每周股票复盘：卫光生物（002880）现332.75万元大宗交易
证券之星 · 06-07
每周股票复盘：卫光生物（002880）现332.75万元大宗交易
卫光生物获得发明专利授权：“一种C1酯酶抑制剂重组变体及其制备方法和应用”
证券之星 · 06-03
卫光生物获得发明专利授权：“一种C1酯酶抑制剂重组变体及其制备方法和应用”
6月3日卫光生物现332.75万元大宗交易
证券之星 · 06-03
6月3日卫光生物现332.75万元大宗交易
卫光生物：公司近年来采浆量保持持续较好增长
证券之星 · 05-29
卫光生物：公司近年来采浆量保持持续较好增长
卫光生物：公司在日常生产经营中持续采取有效措施和方法提升经营效率和效益
证券之星 · 05-29
卫光生物：公司在日常生产经营中持续采取有效措施和方法提升经营效率和效益
卫光生物：公司聚焦血液制品领域始终坚持技术驱动产品研发
证券之星 · 05-04
卫光生物：公司聚焦血液制品领域始终坚持技术驱动产品研发
卫光生物：公司坚持技术驱动研发创新并密切关注前沿技术与运用
证券之星 · 05-04
卫光生物：公司坚持技术驱动研发创新并密切关注前沿技术与运用
卫光生物：二级市场股票价格的短期波动受到多种因素的影响
证券之星 · 04-30
卫光生物：二级市场股票价格的短期波动受到多种因素的影响
卫光生物：园区将通过探索与生物医药领域相关优质企业合作的方式寻找新的利润增长点
证券之星 · 04-30
卫光生物：园区将通过探索与生物医药领域相关优质企业合作的方式寻找新的利润增长点
卫光生物：目前，卫光生命科学园已成功引入40余家机构与企业
证券之星 · 04-30
卫光生物：目前，卫光生命科学园已成功引入40余家机构与企业
卫光生物：公司2024年度采浆量为562吨
证券之星 · 04-30
卫光生物：公司2024年度采浆量为562吨
卫光生物：公司在致力于持续提升盈利能力和内在价值的同时一直坚持实施稳定可以持续的股东回报机制
证券之星 · 04-30
卫光生物：公司在致力于持续提升盈利能力和内在价值的同时一直坚持实施稳定可以持续的股东回报机制
加载更多
公司概况
公司名称：
深圳市卫光生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-06-16
主营业务：
深圳市卫光生物制品股份有限公司的主营业务是生物制品生产、销售及研发。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血因子Ⅷ、人凝血酶原复合物。
发行价格：
25.11
{"stockData":{"symbol":"002880","market":"SZ","secType":"STK","nameCN":"卫光生物","latestPrice":28.99,"timestamp":1752130983000,"preClose":29.19,"halted":0,"volume":1808336,"delay":0,"changeRate":-0.0069,"floatShares":227000000,"shares":227000000,"eps":1.1043,"marketStatus":"已收盘","change":-0.2,"latestTime":"07-10 15:00:00","open":29.17,"high":29.28,"low":28.96,"amount":52608100,"amplitude":0.011,"askPrice":29,"askSize":12,"bidPrice":28.99,"bidSize":27,"shortable":0,"etf":0,"ttmEps":1.1043,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752197400000},"marketStatusCode":5,"adr":0,"adjPreClose":29.19,"symbolType":"stock","openAndCloseTimeList":[[1752111000000,1752118200000],[1752123600000,1752130800000]],"highLimit":32.11,"lowLimit":26.27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":226800000,"isCdr":false,"pbRate":2.94,"roa":"--","peRate":26.251924,"roe":"1.96%","epsLYR":1.1178,"committee":0.641026,"marketValue":6575000000,"turnoverRate":0.008,"status":1,"floatMarketCap":6575000000},"requestUrl":"/m/hq/s/002880","defaultTab":"news","newsList":[{"id":"2550353576","title":"卫光生物：卫光生命科学园再获殊荣，行业标杆意义凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2550353576","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550353576?lang=zh_cn&edition=full","pubTime":"2025-07-09 17:40","pubTimestamp":1752054000,"startTime":"0","endTime":"0","summary":"此次与卫光生命科学园同台获奖的还有中关村生命科学园、天府国际生物城等生物医药领域的知名产业园区。血制品筑基，打造平台化生物医药新锐卫光生命科学园由卫光生物主导建设与运营，成长于全球最具活力的城市深圳。2024年卫光生命科学园产值突破3.57亿元，同比增幅高达48.8%。卫光生命科学园此次作为标杆园区入选优秀案例，无疑证明了园区的独特价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-07-09/doc-infewkcm4765014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0239","002880"],"gpt_icon":0},{"id":"2548416892","title":"卫光生物：原料血浆供应总体能满足生产需要","url":"https://stock-news.laohu8.com/highlight/detail?id=2548416892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548416892?lang=zh_cn&edition=full","pubTime":"2025-07-02 20:53","pubTimestamp":1751460798,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物07月02日在投资者关系平台上答复投资者关心的问题。公司主营产品为血液制品，生产原料为健康人血浆，原料血浆是一种稀缺的宝贵资源。目前公司原料血浆供应总体能满足生产需要。未来，随着公司市场的不断扩大和业务的持续发展，可能会面临原料血浆不足的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200036510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"gpt_icon":0},{"id":"2548864120","title":"卫光生物收盘下跌1.46%，滚动市盈率26.26倍，总市值65.77亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548864120","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548864120?lang=zh_cn&edition=full","pubTime":"2025-07-02 16:53","pubTimestamp":1751446395,"startTime":"0","endTime":"0","summary":"7月2日，卫光生物今日收盘29.0元，下跌1.46%，滚动市盈率PE达到26.26倍，总市值65.77亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均68.07倍，行业中值43.36倍，卫光生物排名第39位。截至2025年一季报，共有5家机构持仓卫光生物，其中其他5家，合计持股数17243.78万股，持股市值46.54亿元。深圳市卫光生物制品股份有限公司的主营业务是生物制品生产、销售及研发。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/02165351440846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0046","002880","BK0239"],"gpt_icon":0},{"id":"2548204000","title":"卫光生物：7月17日将召开2025年第一次临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2548204000","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548204000?lang=zh_cn&edition=full","pubTime":"2025-07-01 22:10","pubTimestamp":1751379000,"startTime":"0","endTime":"0","summary":"证券日报网讯7月1日晚间，卫光生物发布公告称，公司将于2025年7月17日召开2025年第一次临时股东大会。本次股东大会将审议《关于修订<公司章程>并办理工商变更登记的议案》《关于修订公司相关制度的议案》等多项议案。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-07-01/doc-infcytxe3244142.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-07-01/doc-infcytxe3244142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002880","BK0046"],"gpt_icon":0},{"id":"2546484772","title":"卫光生物：坚持内生式增长和外延式并购双驱并进","url":"https://stock-news.laohu8.com/highlight/detail?id=2546484772","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546484772?lang=zh_cn&edition=full","pubTime":"2025-06-25 20:55","pubTimestamp":1750856115,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物(002880)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问：今年以来国药集团关于并购重组的预期越来越大，公司是否积极关注相关机会？卫光生物回复：尊敬的投资者朋友，您好！公司坚持内生式增长和外延式并购双驱并进，积极寻求优质标的的并购机会，助力公司高质量发展。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062500036496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"gpt_icon":0},{"id":"2545373404","title":"卫光生物：公司研发实力不断提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2545373404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545373404?lang=zh_cn&edition=full","pubTime":"2025-06-24 16:54","pubTimestamp":1750755255,"startTime":"0","endTime":"0","summary":"公司近年来获得了人凝血因子Ⅷ、人凝血酶原复合物药品注册证书，近期获得了相关医疗器械生产备案凭证，公司研发实力不断提升。公司根据战略规划、研发进度等情况合理确定每年的研发投入金额，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400027149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002880","BK0239"],"gpt_icon":0},{"id":"2543679824","title":"卫光生物最新公告：获得医疗器械生产备案凭证","url":"https://stock-news.laohu8.com/highlight/detail?id=2543679824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543679824?lang=zh_cn&edition=full","pubTime":"2025-06-16 18:40","pubTimestamp":1750070443,"startTime":"0","endTime":"0","summary":"卫光生物(002880.SZ)公告称，卫光生物近日获得深圳市市场监督管理局出具的《第一类医疗器械生产备案凭证》，备案编号为粤深药监械生产备20250037号。公司表示，此次备案的产品属于第Ⅰ类医疗器械，将增加公司可生产和销售的产品种类，对公司长期经营业绩具有积极影响，但对本年度财务状况不会有重大影响。相关产品的生产和销售情况受多种因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600025533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK1100","09997","BK1574","09996","BK1222","BK0239","BK1583","159883","002880"],"gpt_icon":0},{"id":"2542229773","title":"血液制品概念盘中跳水，卫光生物跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542229773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542229773?lang=zh_cn&edition=full","pubTime":"2025-06-11 09:36","pubTimestamp":1749605779,"startTime":"0","endTime":"0","summary":"06月11日，血液制品概念盘中跳水，截至09点36分，血液制品概念整体指数下跌0.56%，报814.690点。从个股上来看，该概念的成分股中，卫光生物跌0.21%，科华生物、上海莱士、同方股份跌幅居前。从资金上来看，截止发稿，血液制品概念概念主力净流入为-814.73万，其中赛伦生物受到资金热捧，主力净流入588.18万；拉长时间线来看，该板块近20日主力资金净流入-6.54亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506110936199517084f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506110936199517084f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0038","600100","BK0188","BK0196","688163","BK0239","BK0101","BK0026","BK0124","BK0046","002880","BK0045","BK0012","BK0030","BK0041","BK0043","BK0028","BK0122","BK0067","BK0214"],"gpt_icon":0},{"id":"2541164808","title":"每周股票复盘：卫光生物（002880）现332.75万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2541164808","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541164808?lang=zh_cn&edition=full","pubTime":"2025-06-07 15:46","pubTimestamp":1749282369,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘，卫光生物（002880）报收于29.28元，较上周的28.53元上涨2.63%。本周，卫光生物6月4日盘中最高价报29.79元。6月3日盘中最低价报28.49元。卫光生物当前最新总市值66.41亿元，在生物制品板块市值排名35/50，在两市A股市值排名2314/5148。本周关注点交易信息汇总: 6月3日卫光生物现332.75万元大宗交易交易信息汇总6月3日，卫光生物发生了金额为332.75万元的大宗交易。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700012093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0046","BK0239"],"gpt_icon":0},{"id":"2540015677","title":"卫光生物获得发明专利授权：“一种C1酯酶抑制剂重组变体及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2540015677","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540015677?lang=zh_cn&edition=full","pubTime":"2025-06-04 02:47","pubTimestamp":1748976458,"startTime":"0","endTime":"0","summary":"专利摘要：本发明公开了一种C1酯酶抑制剂重组变体及其制备方法和应用。一种C1酯酶抑制剂重组变体，其氨基酸序列如SEQ ID NO.1所示。同时本发明制备方法中加入一定浓度的重组人血清白蛋白可明显提高单细胞扩增成功率，进一步提高单细胞株的获得率，解决了悬浮单细胞增殖活性低、难扩增的问题。今年以来卫光生物新获得专利授权10个，较去年同期增加了400%。结合公司2024年年报财务数据，2024年公司在研发方面投入了4905.28万元，同比减22.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400001166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","002880"],"gpt_icon":0},{"id":"2540721461","title":"6月3日卫光生物现332.75万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2540721461","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540721461?lang=zh_cn&edition=full","pubTime":"2025-06-03 17:17","pubTimestamp":1748942256,"startTime":"0","endTime":"0","summary":"证券之星消息，6月3日卫光生物发生大宗交易，交易数据如下：大宗交易成交价格29.24元，成交11.38万股，成交金额332.75万元，买方营业部为财达证券股份有限公司深圳彩田路证券营业部，卖方营业部为恒泰证券股份有限公司上海古北路证券营业部。近三个月该股共发生1笔大宗交易，合计成交1138.0手。截至2025年6月3日收盘，卫光生物报收于29.24元，上涨2.49%，换手率1.18%，成交量2.67万手，成交额7749.37万元。该股最近90天内共有3家机构给出评级，买入评级3家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060300024852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","002880"],"gpt_icon":0},{"id":"2539269512","title":"卫光生物：公司近年来采浆量保持持续较好增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2539269512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539269512?lang=zh_cn&edition=full","pubTime":"2025-05-29 22:27","pubTimestamp":1748528839,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物(002880)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司2025年采血浆目标是多少，是否手上有申请的采浆站卫光生物回复：尊敬的投资者朋友，您好！公司近年来采浆量保持持续较好增长，2025年度将继续深挖现有浆站采浆潜力，并加大力量获取新浆站，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052900037317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","BK0046"],"gpt_icon":0},{"id":"2539269541","title":"卫光生物：公司在日常生产经营中持续采取有效措施和方法提升经营效率和效益","url":"https://stock-news.laohu8.com/highlight/detail?id=2539269541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539269541?lang=zh_cn&edition=full","pubTime":"2025-05-29 22:24","pubTimestamp":1748528662,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物05月29日在投资者关系平台上答复投资者关心的问题。公司在日常生产经营中持续采取有效措施和方法提升经营效率和效益，进行相关数字化监管体系建设，全力提升产品全生命周期智慧管控水平和效率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052900037305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002880","BK0239"],"gpt_icon":0},{"id":"2532397191","title":"卫光生物：公司聚焦血液制品领域始终坚持技术驱动产品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2532397191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532397191?lang=zh_cn&edition=full","pubTime":"2025-05-04 14:36","pubTimestamp":1746340569,"startTime":"0","endTime":"0","summary":"请问“稻米造血”技术的发展可能为卫光生物带来新的技术思路和合作机会，促进贵公司在生物制品领域的技术升级和产品多元化发展吗？！公司聚焦血液制品领域，始终坚持技术驱动产品研发，密切关注市场动态和行业前沿技术与应用，不断提高自身技术研发实力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050400001019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"gpt_icon":0},{"id":"2532397198","title":"卫光生物：公司坚持技术驱动研发创新并密切关注前沿技术与运用","url":"https://stock-news.laohu8.com/highlight/detail?id=2532397198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532397198?lang=zh_cn&edition=full","pubTime":"2025-05-04 14:33","pubTimestamp":1746340388,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物(002880)05月04日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在抗衰老蛋白方面是否有技术储备？近期各地大三甲医院纷纷开设抗衰老门诊，门诊业务量大幅度增加，公司既然在血制品方面难有建树，何不另辟赛道，进军美容消费这个行业。卫光生物回复：尊敬的投资者朋友，您好！公司坚持技术驱动研发创新，并密切关注前沿技术与运用，不断增强自身研发实力，寻找新的利润增长点。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050400001018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","BK0046"],"gpt_icon":0},{"id":"2531085327","title":"卫光生物：二级市场股票价格的短期波动受到多种因素的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085327","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531085327?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:39","pubTimestamp":1746005953,"startTime":"0","endTime":"0","summary":"投资者提问：卫光生物第三期员工持股计划成交均价为28.89，当前每股已低两块，并且股价长期位于持股成本线下方，这难道不会对员工积极性造成影响？二级市场股票价格的短期波动受到多种因素的影响，参加公司第三期员工持股计划的人员范围涵盖公司或公司的控股子公司董事、监事、高级管理人员和骨干员工，上述人员对公司未来发展充满信心，并将努力奋斗，与公司共同成长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000035760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","002880"],"gpt_icon":0},{"id":"2531324085","title":"卫光生物：园区将通过探索与生物医药领域相关优质企业合作的方式寻找新的利润增长点","url":"https://stock-news.laohu8.com/highlight/detail?id=2531324085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531324085?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:39","pubTimestamp":1746005948,"startTime":"0","endTime":"0","summary":"园区除了物业出租收入外，还将通过探索与生物医药领域相关优质企业合作的方式，寻找新的利润增长点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000035757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002880","BK0239","161726","399441"],"gpt_icon":0},{"id":"2531887000","title":"卫光生物：目前，卫光生命科学园已成功引入40余家机构与企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2531887000","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531887000?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:21","pubTimestamp":1746004898,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物(002880)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司科学园都有哪些医药创新项目？卫光生物回复：尊敬的投资者朋友，您好！目前，卫光生命科学园已成功引入40余家机构与企业，其中包括唐颐控股、深信生物、粒影生物、三启生物等，详细情况可关注“卫光生命科学园”微信公众号，查阅相关内容。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000034622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002880","BK0239"],"gpt_icon":0},{"id":"2531707022","title":"卫光生物：公司2024年度采浆量为562吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531707022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531707022?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:01","pubTimestamp":1746003698,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物(002880)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司年采血量是多少吨？卫光生物回复：尊敬的投资者朋友，您好！公司2024年度采浆量为562吨。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000033993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","002880"],"gpt_icon":0},{"id":"2531970780","title":"卫光生物：公司在致力于持续提升盈利能力和内在价值的同时一直坚持实施稳定可以持续的股东回报机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2531970780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531970780?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:57","pubTimestamp":1746003436,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物04月30日在投资者关系平台上答复投资者关心的问题。公司在致力于持续提升盈利能力和内在价值的同时，一直坚持实施稳定、可以持续的股东回报机制，根据公司发展的不同阶段并考虑股东回报水平，制定合理的利润分配方案，最大程度保障全体股东的利益，让全体股东共享公司发展成果，不断增强全体股东的认同感和获得感。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000033800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752153475648,"stockEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0034},{"period":"3month","weight":-0.0727},{"period":"6month","weight":0.1402},{"period":"1year","weight":0.0518},{"period":"ytd","weight":0.0807}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0274},{"period":"3month","weight":0.0836},{"period":"6month","weight":0.1024},{"period":"1year","weight":0.1803},{"period":"ytd","weight":0.0422}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳市卫光生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10540人(较上一季度减少4.14%)","perCapita":"21518股","listingDate":"2017-06-16","address":"广东省深圳市光明区光明街道碧眼社区光侨大道3402号办公楼一层","registeredCapital":"22680万元","survey":" 深圳市卫光生物制品股份有限公司的主营业务是生物制品生产、销售及研发。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血因子Ⅷ、人凝血酶原复合物。","listedPrice":25.11},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"卫光生物(002880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供卫光生物(002880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"卫光生物,002880,卫光生物股票,卫光生物股票老虎,卫光生物股票老虎国际,卫光生物行情,卫光生物股票行情,卫光生物股价,卫光生物股市,卫光生物股票价格,卫光生物股票交易,卫光生物股票购买,卫光生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"卫光生物(002880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供卫光生物(002880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}